نتایج جستجو برای: mycn

تعداد نتایج: 1228  

Journal: :Frontiers in Pharmacology 2023

Immunotherapy for neuroblastoma remains unsatisfactory due to heterogeneity and weak immunogenicity. Exploring powerful signatures the evaluation of immunotherapy outcomes remain primary purpose. We constructed a ferroptosis-related gene (FRG) signature by least absolute shrinkage selection operator Cox regression, identified 10 independent prognostic FRGs in training cohort (GSE62564), then ve...

2014
STEPHANIE S. WANG RUTH HSIAO MARIKO M. LIMPAR SARAH LOMAHAN TUAN-ANH TRAN NOLAN J. MALONEY NAOHIKO IKEGAKI XAO X. TANG

In the present study, we investigated the anticancer effects of the mitochondrial inhibitors, metaiodobenzylguanidine (MIBG), metformin and phenformin. 131I-MIBG has been used for scintigraphic detection and the targeted radiotherapy of neuroblastoma (NB), a pediatric malignancy. Non-radiolabeled MIBG has been reported to be cytotoxic to NB cells in vitro and in vivo. However, the mechanisms be...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Kensuke Tateishi A John Iafrate Quan Ho William T Curry Tracy T Batchelor Keith T Flaherty Maristela L Onozato Nina Lelic Sudhandra Sundaram Daniel P Cahill Andrew S Chi Hiroaki Wakimoto

PURPOSE Deregulated Myc drives an oncogenic metabolic state, including pseudohypoxic glycolysis, adapted for the constitutive production of biomolecular precursors to feed rapid tumor cell growth. In glioblastoma, Myc facilitates renewal of the tumor-initiating cell reservoir contributing to tumor maintenance. We investigated whether targeting the Myc-driven metabolic state could be a selective...

Journal: :Neoplasia 2008
Louis Chesler David D Goldenberg Rodney Collins Matt Grimmer Grace E Kim Tarik Tihan Kim Nguyen Slava Yakovenko Katherine K Matthay William A Weiss

Chemoresistance in neuroblastoma is a significant issue complicating treatment of this common pediatric solid tumor. MYCN-amplified neuroblastomas are infrequently mutated at p53 and are chemosensitive at diagnosis but acquire p53 mutations and chemoresistance with relapse. Paradoxically, Myc-driven transformation is thought to require apoptotic blockade. We used the TH-MYCN transgenic murine m...

2012
Vito Pistoia Fabio Morandi Annalisa Pezzolo Lizzia Raffaghello Ignazia Prigione

MYCN is a well-known oncogene over-expressed in different human malignancies including neuroblastoma (NB), rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms' tumor, and small cell lung cancer. In the case of NB, MYCN amplification is an established biomarker of poor-prognosis. MYCN belongs to a family of transcription factors (the most important of which is C-MYC) that show a high degree of...

Journal: :The American Journal of Pathology 1999

Journal: :Cold Spring Harbor Perspectives in Medicine 2013

Journal: :Journal of Investigative Dermatology 2022

Basal cell carcinoma (BCC) is driven by constitutive activation of the Hedgehog (Hh) signaling pathway, most commonly through loss-of-function mutations in PTCH1. Using animal models, we demonstrate here that microscopic BCC-like tumors initiated loss Ptch1 or gain Smo fail to progress and eventually enter into a dormant state. Because NOTCH1/2 TRP53 are detected human BCC, sought determine if ...

Journal: :Molecular medicine reports 2009
Ana Patrícia Barros Cordeiro Fábio P E da Silva Julio Cesar Pieczarka Cleusa Yoshiko Nagamachi Nilson Praia Anselmo José Reginaldo Brito Douglas S Vasconcelos Thomas Liehr Anja Weise Edivaldo H C de Oliveira

Meningiomas are generally slow-growing benign tumours; however, recurrent cases are associated with a poor prognosis. As these tumours are commonly grouped according to their grade of malignancy, it is difficult to define tumour-specific alterations involved in their genesis and evolution. Genetic comparative studies of primary and recurrent tumours are important for the identification of the c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید